SafeBeat Receives Supplement Award for UCSF Phase II SBIR Grant. Advancing Dr. Margaret Ferrari’s Career Development.

 

SafeBeat has been awarded a supplement award as part of its Phase Il SBIR grant by the National Institutes of Health (NIH) – National Heart, Lung, and Blood Institute (NHLBI) and in collaboration with the University of California, San Francisco (UCSF). The funding will support Dr. Margaret Ferrari, Ph.D., a Post-doctoral Fellow at SafeBeat, advancing her career development in the field of cardiac care innovation.

This award enables Dr. Ferrari to further contribute to the groundbreaking work being conducted at SafeBeat, particularly in developing Al-driven solutions for heart rhythm disorder management. SafeBeat is revolutionizing how patients initiate and manage cardiac therapeutics through innovative engineering and technology.

SafeBeat is proud to support talented researchers like Dr. Ferrari as they pioneer advancements that improve patient outcomes and expand access to cutting-edge healthcare technologies.

SafeBeat is at the forefront of cardiac innovation, aiming to transform how heart rhythm conditions are monitored and treated through advanced engineering and technology.

About SafeBeat:
SafeBeat is a digital health company developing an ECG analysis Al model to enable patients with atrial fibrillation to take cardiac medications while being monitored by their clinical team, all from a phone. SafeBeat is backed by top early stage venture capital investors
including Y Combinator, 50 Years, Fusion Fund, and top angel investors.

For media inquiries or to learn more about SafeBeat’s technologies, please contact:SafeBeat Communications Team
Email: info@safebeatrx.com